Magenta Therapeutics, Inc. acquired target

Magenta Therapeutics, Inc. -> target · $70 million

(“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-st